Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 134.0% in January

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 12,400 shares, an increase of 134.0% from the December 31st total of 5,300 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their target price on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, January 13th.

Barinthus Biotherapeutics Trading Up 0.5 %

Shares of BRNS stock traded up $0.01 on Friday, reaching $1.01. 13,858 shares of the stock were exchanged, compared to its average volume of 41,033. The company has a market capitalization of $40.43 million, a price-to-earnings ratio of -0.67 and a beta of -0.81. The business’s 50 day moving average price is $1.03 and its 200 day moving average price is $1.21. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The business had revenue of $14.97 million during the quarter. During the same quarter in the prior year, the firm posted ($0.37) EPS. Equities research analysts forecast that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.